Clinical Trials Logo

Splenomegaly clinical trials

View clinical trials related to Splenomegaly.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT02298699 Withdrawn - Developmental Delay Clinical Trials

Biomarker for Sly Disease (MPS VII) (BioSly)

BioSly
Start date: August 20, 2018
Phase:
Study type: Observational

Development of a new MS-based biomarker for the early and sensitive diagnosis of Sly disease from blood (plasma)

NCT ID: NCT02298647 Withdrawn - Seizures Clinical Trials

Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)

BioGM1/BioGM2
Start date: August 20, 2018
Phase:
Study type: Observational

Development of a new MS-based biomarker for the ear-ly and sensitive diagnosis of GM1/GM2 from blood

NCT ID: NCT02298634 Withdrawn - Splenomegaly Clinical Trials

Biomarker for Farber Disease (BioFarber)

BioFarber
Start date: August 20, 2018
Phase:
Study type: Observational

Development of a new mass spectrometry-based biomarker for the early and sensitive diagnosis of Farber disease from the blood

NCT ID: NCT01785979 Withdrawn - Malaria Clinical Trials

Prednisone Plus Chloroquine for the Treatment of Hyper-reactive Malarial Splenomegaly

LiHMS
Start date: January 2016
Phase: Phase 3
Study type: Interventional

This randomized clinical trial will address a complication related to recurrent episodes of malaria in endemic areas - hyper-reactive malarial splenomegaly. We aim to assess the efficacy of chloroquine after prednisone-induction therapy compared to standard treatment of chloroquine alone in the treatment of adult patients with newly diagnosed hyper-reactive malarial splenomegaly.

NCT ID: NCT01457443 Withdrawn - Lung Disease Clinical Trials

Biomarker for Pompe Disease (BioPompe)

BioPompe
Start date: August 20, 2018
Phase:
Study type: Observational

Development of a new MS-based biomarker for the early and sensitive diagnosis of Pompe disease from blood (plasma)

NCT ID: NCT01331642 Withdrawn - Splenomegaly Clinical Trials

Biomarker for Gaucher Disease: BioGaucher (BioGaucher)

BioGaucher
Start date: August 20, 2018
Phase:
Study type: Observational

Development of a new mass spectrometry-based biomarker for the early and sensitive diagnosis of Gaucher Disease from blood (plasma)